If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
28.50    0.00 (0.00%)
Bid:
28.00
Ask:
29.00
Spread: 1.00 (3.571%)
Market Cap: £51.54m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Result of Placing

11 Jul 2018 13:19

RNS Number : 3380U
Ilika plc
11 July 2018
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

 

 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

For immediate release

11 July 2018

Ilika plc

 

Result of Placing

 

Ilika plc, the advanced solid-state battery technology and materials innovation company ("Ilika", the "Company" or, together with its subsidiary undertakings, the "Group"), is pleased to announce that, following the announcement earlier today (the "Launch Announcement") regarding the launch of a proposed placing (the "Placing"), it has successfully placed 20,224,683 new ordinary shares of one penny each (the "Ordinary Shares") (the "Placing Shares") at a price of 20 pence per share (the "Placing Price") raising gross proceeds of approximately £4.0 million.

 

Liberum Capital Limited ("Liberum") acted as sole bookrunner on the Placing.

 

The Placing Price represents a discount of approximately 13.0 per cent. to the closing price of 23 pence per Ordinary Share on 10 July 2018, being the last business day prior to the announcement of the Placing.

 

The Placing is conditional upon, amongst other things:

 

· the Placing Agreement becoming unconditional in all respects (save for Admission) and not having been terminated in accordance with its terms;

· the Resolutions being passed at the General Meeting by the requisite majorities; and

· Admission of the Placing Shares to trading on AIM becoming effective.

 

Application will be made for the Placing Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on 30 July 2018.

 

As announced earlier today, Ilika also intends to raise up to approximately £1.0 million through the issue of 5,058,240 new Ordinary Shares (the "Open Offer Shares") pursuant to an open offer (the "Open Offer", together with the Placing, the "Capital Raising"), to allow Ilika shareholders who are not participating in the Placing to subscribe for new Ordinary Shares at the Placing Price. The Company intends to send a circular to shareholders in connection with the Open Offer on or around 11 July 2018. The Circular will also be available on the Company's website: www.ilika.com.

 

Related Party Transaction

 

Sapia Partners LLP, Henderson Global Investors Limited and Hargreave Hale Ltd, who are conditionally subscribing for 2.5m, 2.0m and 3.7m Placing Shares at the Placing Price respectively, by virtue of them holding more than 10 per cent. of the existing issued share capital of the Company, are considered to be related parties of the Company and their participation in the Placing is therefore a related party transaction under the AIM Rules for Companies. The Directors consider, having consulted with Liberum, the Company's nominated adviser, that the terms of the Placing are fair and reasonable in so far as its shareholders are concerned.

 

Director Subscriptions

The following directors have subscribed for New Ordinary Shares in the following amounts and pursuant to the Director Subscription Agreements:

Director

Existing beneficial shareholding

New Ordinary Shares subscribed for

Shareholding on completion of the Placing

Shareholding as a percentage of the Enlarged Issued Share Capital

Mike Inglis

115,000

250,000

365,000

0.35 per cent.

Graeme Purdy

609,427

125,000

734,427

0.71 per cent.

Keith Jackson

20,000

50,000

70,000

0.07 per cent.

 

Capitalised terms not defined in this Announcement have the meaning given to them in the Launch Announcement.

 

For more information contact:

 

Ilika plc

 

 

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

Liberum Capital Limited

Tel: 020 3100 2000

Neil Elliot, Jill Li,

Trystan Cullen, William Hall

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Paul Cornelius

Mob: 07866 384 707

Lianne Cawthorne

Mob: 07584 391 303

 

Note:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain. If you have any queries on this, then please contact Steve Boydell, Finance Director of the Company (responsible for arranging release of this announcement) on 023 8011 1400.

 

 

IMPORTANT NOTICES

This Announcement may contain and the Company may make verbal statements containing "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. Forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "seek", "may", "could", "outlook" or other words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company, including amongst other things, United Kingdom domestic and global economic business conditions, market-related risks such as fluctuations in interest rates and exchange rates, the policies and actions of governmental and regulatory authorities, the effect of competition, inflation, deflation, the timing effect and other uncertainties of future acquisitions or combinations within relevant industries, the effect of tax and other legislation and other regulations in the jurisdictions in which the Company and its affiliates operate, the effect of volatility in the equity, capital and credit markets on the Company's profitability and ability to access capital and credit, a decline in the Company's credit ratings; the effect of operational risks; and the loss of key personnel. As a result, the actual future financial condition, performance and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Any forward-looking statements made in this Announcement by or on behalf of the Company speak only as of the date they are made. Except as required by applicable law or regulation, the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

 

Liberum is authorised and regulated by the Financial Conduct Authority (the "FCA") in the United Kingdom and is acting exclusively for the Company and no one else in connection with the Placing or any other matters referred to in this Announcement, and Liberum will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

 

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Liberum or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

 

No statement in this Announcement is intended to be a profit forecast or estimate, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

 

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

 

The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than the London Stock Exchange.

 

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROIBDGDRLBBBGIB
Date   Source Headline
3rd Jul 20267:05 amRNSRetail Offer for up to £0.5 million
3rd Jul 20267:00 amRNSResult of Placing & Director Subscription
2nd Jul 20265:08 pmRNSProposed Capital Raising to raise £5.0 million
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.